FAQ on Calidi Biotherapeutics Inc. (NYSE American: CLDI) Q2 2025 Results and Business Highlights
Summary
What were Calidi Biotherapeutics’ Q2 2025 financial results?
Calidi Biotherapeutics reported a Q2 2025 net loss of $5.7 million, or $1.99 per share, an improvement from a net loss of $7.4 million, or $16.75 per share, in Q2 2024. R&D expenses were $2.6 million, and G&A expenses were $3.1 million.
What recent business highlights did Calidi Biotherapeutics announce?
Recent highlights include new preclinical data on CLD-401, $4.6 million raised in a warrant inducement offering, bringing 2025 gross proceeds to $15.7 million, and FDA Fast Track Designation for CLD-201 in soft tissue sarcoma.
What is the RedTail platform?
The RedTail platform is Calidi Biotherapeutics’ proprietary technology featuring an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites, intended to shield the virus from immune clearance and deliver gene therapies to metastatic locations.
What is the significance of the FDA Fast Track Designation for CLD-201?
The FDA Fast Track Designation for CLD-201 in soft tissue sarcoma accelerates the development and review process, highlighting the potential of CLD-201 to address unmet medical needs in this area.
How much cash did Calidi Biotherapeutics have at the end of Q2 2025?
Calidi Biotherapeutics ended Q2 2025 with $5.3 million in cash and $0.1 million in restricted cash.
What is Calidi Biotherapeutics’ lead candidate from the Redtail platform targeting?
The lead candidate from the Redtail platform is currently in IND-enabling studies targeting non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need.
Where can I find more information about Calidi Biotherapeutics?
More information about Calidi Biotherapeutics is available in the company’s newsroom at https://ibn.fm/CLDI.
What is TinyGems?
TinyGems is a specialized communications platform focusing on innovative small-cap and mid-cap companies with significant potential, part of the Dynamic Brand Portfolio at IBN.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 143783